Sarepta Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €1.17B -1.9% €176.94M +6.5% 15.1% +0.012 pp €221.42M -18.8% 18.9% -0.039 pp
    (estimated) €1.20B -8.2% €166.22M -27.3% 13.9% -0.036 pp €272.68M -16.4% 22.8% -0.022 pp
    (estimated) €1.30B -3.5% €228.49M -6.0% 17.5% -0.0046 pp €326.19M +42.0% 25.0% +0.080 pp
    (estimated) €1.35B -23.4% €243.04M -166.2% 18.0% +0.39 pp €229.71M -199.6% 17.0% +0.30 pp
    (estimated) €1.76B +7.6% -€367.11M -281.1% -20.8% -0.33 pp -€230.63M +288.9% -13.1% -0.095 pp
    €1.64B +53.0% €202.67M -143.9% 12.4% +0.55 pp -€59.30M -83.8% -3.6% +0.31 pp
    €1.07B +33.3% -€461.77M -23.8% -43.1% +0.32 pp -€366.06M +44.3% -34.2% -0.026 pp
    €803.84M +32.9% -€606.09M +68.0% -75.4% -0.16 pp -€253.75M -27.2% -31.6% +0.26 pp
    €604.71M +30.0% -€360.80M -24.4% -59.7% +0.43 pp -€348.65M -313.4% -57.7% -0.93 pp
    €465.32M +41.8% -€477.41M -22.5% -102.6% +0.85 pp €163.41M -148.2% 35.1% +1.4 pp
    €328.11M +26.5% -€616.07M +97.6% -187.8% -0.68 pp -€339.23M +21.4% -103.4% +0.043 pp
    €259.36M +94.7% -€311.81M +614.0% -120.2% -0.87 pp -€279.41M +53.9% -107.7% +0.29 pp
    €133.18M +2,751.6% -€43.67M -81.0% -32.8% +49 pp -€181.60M -11.8% -136.4% +43 pp
    €4.67M +332.6% -€230.26M +21.5% -4,930.2% +130 pp -€205.87M +65.2% -4,407.9% +71 pp
    €1.08M -87.2% -€189.57M +62.0% -17,560.3% -160 pp -€124.61M +42.2% -11,542.9% -110 pp
    €8.41M -31.4% -€116.99M +21.3% -1,391.7% -6.0 pp -€87.63M +67.0% -1,042.5% -6.1 pp
    €12.25M -61.9% -€96.48M -7.7% -787.6% -4.6 pp -€52.49M +113.4% -428.4% -3.5 pp
    €32.16M -20.6% -€104.49M +5,132.4% -324.9% -3.2 pp -€24.60M +33.6% -76.5% -0.31 pp
    €40.48M +59.7% -€2.00M -92.8% -4.9% +1.0 pp -€18.41M +61.3% -45.5% -0.0043 pp
    €25.35M +67.3% -€27.72M +27.9% -109.4% +0.34 pp -€11.42M +94.8% -45.1% -0.064 pp
    €15.15M -17.3% -€21.68M +5.0% -143.1% -0.30 pp -€5.86M -38.8% -38.7% +0.14 pp
    €18.31M +93.5% -€20.64M -11.8% -112.7% +1.3 pp -€9.58M -50.7% -52.3% +1.5 pp
    €9.46M +9,428.2% -€23.41M -12.6% -247.3% +270 pp -€19.43M +17.7% -205.3% +160 pp
    €99.33K -97.6% -€26.77M +86.3% -26,951.8% -270 pp -€16.51M +45.1% -16,618.4% -160 pp
    €4.12M +1,011.3% -€14.37M -32.7% -348.6% +54 pp -€11.37M -41.9% -276.0% +50 pp
    €370.86K -55.6% -€21.35M +69.5% -5,756.1% -42 pp -€19.57M +43.4% -5,276.1% -36 pp
    €835.59K +15.9% -€12.59M -50.2% -1,507.1% +20 pp -€13.65M -9.4% -1,633.3% +4.6 pp
    €720.93K +18.5% -€25.29M +9.0% -3,508.6% +3.0 pp -€15.06M +102.3% -2,089.6% -8.7 pp
    €608.34K -45.6% -€23.20M +191.4% -3,813.2% -31 pp -€7.45M +4.0% -1,224.3% -5.8 pp
    €1.12M +1,197.3% -€7.96M +11.3% -712.2% +76 pp -€7.16M +12.4% -641.0% +68 pp
    €86.15K -50.0% -€7.15M -68.9% -8,300.0% +51 pp -€6.38M +68.2% -7,400.0% -52 pp
    €172.31K +100.0% -€23.00M +641.7% -13,350.0% -98 pp -€3.79M +63.0% -2,200.0% +5.0 pp
    €86.15K +0.0% -€3.10M +71.4% -3,600.0% -15 pp -€2.33M +80.0% -2,700.0% -12 pp
    €86.15K +0.0% -€1.81M -19.2% -2,100.0% +5.0 pp -€1.29M -0.7% -1,500.0% +0.10 pp
    €86.15K -€2.24M -2,600.0% -€1.30M -1,510.0%

    Notifications